Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rosuvastatin on Endothelial Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infection~* Age \> 18 years old~* On stable antiretroviral therapy for \> 6 months with no plans to change therapy during the treatment phase of the study~* Plasma HIV RNA \< 50 copies/mL~* Karnofsky performance score \> 70 within 30 days prior to study entry~* Ability to understand and sign informed consent~* Following laboratory values obtained within 30 days prior to randomization:~  * Absolute neutrophil count (ANC) \> 750/mm3~ * Hemoglobin \>/= 8.0 g/dL~ * Platelets \>/= 50,000/mm3~ * ALT (SGPT) and AST (SGOT) \< 2.5 x ULN~ * Fasting glucose \< 126 mg/dL~ * TSH \< 3.0 mIU/L~* HDL-C \< 50 mg/dL in men, \< 55 mg/dL in women~* Direct LDL-C \</= 130 mg/dL~* Calculated creatinine clearance \> 50 mL/min~* Willing to be treated with rosuvastatin or be on an observational arm for a minimum of 3 months~* Female subject must not participate in a conception process (active attempt to become pregnant) or be post-menopausal. If participating in sexual activity that could lead to pregnancy, the subject must use contraception while receiving study medication and 30 days after stopping the medication~Exclusion criteria~* History of past cardiovascular event~* Acute illnesses or active AIDS-defining opportunistic infection (OI) within 30 days prior to entry~* Other chronic illness including diabetes, autoimmune diseases, and endocrinopathies~* Serology positive for hepatitis B surface antigen or hepatitis C antibody~* Signs and symptoms of liver failure~* Receipt of supraphysiologic glucocorticoid therapy within 3 months prior to study entry~* Use of lipid lowering agents within 30 days prior to study entry~* Receipt of an HIV vaccine or investigational agents~* Pregnancy or breast-feeding~* Presence of any active malignancy within the last 5 years~* Severe Hypertension (Systolic \>/= 180 or Diastolic \>/= 110 mm Hg)~* Use of oral postmenopausal hormone replacement therapy~* Known hypersensitivity to rosuvastatin~* Active drug or alcohol dependence~* Any acute illness within 30 days prior to study entry that, in the opinion of the site investigator, would interfere with participation in the study.~* Use of lopinavir/ritonavir (Kaletra) as part of current HIV antiretroviral regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- rosuvastatin (Type: EXPERIMENTAL): rosuvastatin 10 mg qd increased to 20 mg qd as tolerated

Based on this trial design, predict the completion outcome and termination type (if applicable).